RT Journal Article
SR Electronic
T1 Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1665
OP 1676
VO 37
IS 4
A1 MIYUKI MABUCHI
A1 MASAHIRO UEDA
A1 YURI YOSHIDA
A1 KOTA HORIIKE
A1 KENTA YAMAOKA
A1 SYUHEI NAKAO
A1 TADASHI SHIMIZU
A1 YUKO UEDA
A1 KAZUTAKE TSUJIKAWA
A1 AKITO TANAKA
YR 2017
UL http://ar.iiarjournals.org/content/37/4/1665.abstract
AB The inhibitory activities of docetaxel at a wide range of doses (0.1-10 mg/kg; subcutaneously (s.c.), once/week) in nude mice bearing a human prostate cancer cell (DU145), xenograft model with implantation of DU145 cells or a DU145 solid tumor were examined. This systematic trial demonstrated that (i) docetaxel was more effective in the xenograft model formed by implantation of DU145 cells than in the solid DU145 tumor; (ii) administration of 2.5 mg/kg docetaxel was the critical dose because inhibitory activities were not observed at 2.5 mg/kg, while they were noted at 5 mg/kg and 10 mg/kg in both implantation approaches; (iii) edema-like effects (plump body shape and legs) were observed in both groups at 2.5 mg/kg and the tumor sizes, often increased by blood plasma and other fluids, as well as body weights were higher than at other doses; and (iv) suppression of body weight gain was observed at 10 mg/kg docetaxel.